Related Experiment Video

Updated: Apr 30, 2026

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity
09:32

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity

Published on: October 17, 2025

661

Lapatinib

Minna Nolting1, Tanja Schneider-Merck, Martin Trepel

  • 1Department of Oncology and Hematology, Hubertus Wald Cancer Center, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Germany.

Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer
|April 24, 2014
PubMed

Insights

Lapatinib, a dual tyrosine kinase inhibitor, effectively treats advanced HER2-positive breast cancer by blocking HER1 and HER2. It offers an alternative to trastuzumab with fewer cardiac side effects.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • The human epidermal growth factor receptor (HER) family, particularly HER2, is crucial for the growth and survival of various cancer cells, including breast and gastric cancers.
  • Overexpression of HER2 in breast cancer patients is linked to a poor prognosis, but HER2-targeted therapies like trastuzumab have shown significant improvements.
  • Lapatinib is a dual tyrosine kinase inhibitor (TKI) targeting HER1 and HER2.

Purpose of the Study:

  • To evaluate the efficacy and tolerability of lapatinib as a targeted therapy for advanced HER2-positive breast cancer.
  • To investigate lapatinib's mechanism of action in inhibiting tumor cell growth by blocking HER1 and HER2 tyrosine kinase activity.
  • To compare lapatinib's safety profile, particularly cardiac effects, with that of trastuzumab.

Main Methods:

  • Lapatinib inhibits tumor cell growth by binding to the intracellular ATP-binding site of HER1 and HER2, blocking their tyrosine kinase activity.
  • Clinical studies assessed lapatinib's effectiveness in patients with advanced HER2-positive breast cancer, including those with progressive disease after standard therapies.
  • Adverse effects, especially cardiac function, were monitored to evaluate the drug's tolerability.

Main Results:

  • Lapatinib demonstrated efficacy in treating advanced HER2-positive breast cancer, leading to its approval in combination with capecitabine in 2007.
  • The drug is generally well-tolerated, with mostly low-grade adverse effects and minimal cardiac impact compared to trastuzumab.
  • Approval was expanded in 2010 to include postmenopausal women with advanced, hormone receptor- and HER2-positive breast cancer.

Conclusions:

  • Lapatinib is an effective and well-tolerated targeted therapy for advanced HER2-positive breast cancer.
  • Its distinct mechanism and favorable cardiac safety profile make it a valuable treatment option, especially for patients progressing on other therapies.
  • Ongoing research is exploring lapatinib's potential in neoadjuvant/adjuvant settings, combination therapies, and other HER2-positive tumor types.

More Related Videos

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-308:36

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

1.8K
Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

19.0K

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
689
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.1K